ReviewMarine drugs2015
Genipin-Crosslinked Chitosan Gels and Scaffolds for Tissue Engineering and Regeneration of Cartilage and Bone.
Review in Marine drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 287 citations in OpenAlex.
- Upcycling Industrial Lignin Into Cationic Hydrogels With Potential for Sustainable Plant Protection.ChemSusChem · 2026Article
- Review
- Molecularly Imprinted Polymers Based on Cyclodextrin Derivatives and Chitosan for Selective Extraction of Drugs and Dyes.International journal of molecular sciences · 2026Article
- A Multi-Functional Prebiotic Strategy: Crosslinked 2'-Fucosyllactose-Potato Protein Hydrolysate Conjugates Encapsulating Resveratrol for Co-Delivery to Beneficial Gut Bacteria.Foods (Basel, Switzerland) · 2026Article
- Functional Chitosan-Interpenetrating Networks: Next Generation Super-Adsorbents for Biomedical Applications.Polymers · 2026Review
- Nanoengineered Chitosan-Genipin Coating of Yeast-Derived Biopolymer Microcapsules for Theranostic Applications.Polymers · 2026Article
- Chitosan based smart injectable hydrogels for biomedical applications: A comprehensive review.Bioactive materials · 2026Review
- Progressing Regenerative Medicine: Integrating Bioprinting Platforms for Stem Cell Applications.Stem cells international · 2026Review
- Chitosan Sponges as Next-Generation Biomaterials for Dental Tissue Engineering and Periodontal Regeneration.Pharmaceutics · 2025Review
- Regenerative potential of PRP-based scaffolds in chronic wound healing: Mechanisms, advances, and therapeutic insights.Regenerative therapy · 2025Review
- Chemical Crosslinking of Acid Soluble Collagen Fibres.Biomimetics (Basel, Switzerland) · 2025Review
- Review
- Perspectives on the pH-Influenced Design of Chitosan-Genipin Nanogels for Cell-Targeted Delivery.Pharmaceutics · 2025Article
- Design and Evaluation of a Crosslinked Chitosan-Based Scaffold Containing Hyaluronic Acid for Articular Cartilage Reconstruction.Molecules (Basel, Switzerland) · 2025Article
- Feasibility of Genipin to Evaluate Chitosan Rainfastness for Biopesticide Applications.International journal of molecular sciences · 2025Article
- Genipin-Simple but Significant Bioactive Iridoid for Therapeutical Application and Beyond: A Review.Life (Basel, Switzerland) · 2025Review
- Advances and Challenges in Polymer-Based Scaffolds for Bone Tissue Engineering: A Path Towards Personalized Regenerative Medicine.Polymers · 2024Review
- Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy.Journal of translational medicine · 2024Review
- A Novel Bio-Adhesive Based on Chitosan-Polydopamine-Xanthan Gum for Glass, Cardboard and Textile Commodities.Polymers · 2024Article
- Genipin's potential as an anti-cancer agent: from phytochemical origins to clinical prospects.Medical oncology (Northwood, London, England) · 2024Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present review article intends to direct attention to the technological advances made since 2009 in the area of genipin-crosslinked chitosan (GEN-chitosan) hydrogels. After a concise introduction on the well recognized characteristics of medical grade chitosan and food grade genipin, the properties of GEN-chitosan obtained with a safe, spontaneous and irreversible chemical reaction, and the quality assessment of the gels are reviewed. The antibacterial activity of GEN-chitosan has been well assessed in the treatment of gastric infections supported by Helicobacter pylori. Therapies based on chitosan alginate crosslinked with genipin include stem cell transplantation, and development of contraction free biomaterials suitable for cartilage engineering. Collagen, gelatin and other proteins have been associated to said hydrogels in view of the regeneration of the cartilage. Viability and proliferation of fibroblasts were impressively enhanced upon addition of poly-l-lysine. The modulation of the osteocytes has been achieved in various ways by applying advanced technologies such as 3D-plotting and electrospinning of biomimetic scaffolds, with optional addition of nano hydroxyapatite to the formulations. A wealth of biotechnological advances and know-how has permitted reaching outstanding results in crucial areas such as cranio-facial surgery, orthopedics and dentistry. It is mandatory to use scaffolds fully characterized in terms of porosity, pore size, swelling, wettability, compressive strength, and degree of acetylation, if the osteogenic differentiation of human mesenchymal stem cells is sought: in fact, the novel characteristics imparted by GEN-chitosan must be simultaneously of physico-chemical and cytological nature. Owing to their high standard, the scientific publications dated 2010-2015 have met the expectations of an interdisciplinary audience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.